The emerging role of XBP1 in cancer - 30/05/20
, Jing Chen b, Xin Hua a, Yue Sun a, Rui Cui a, Jun Sha a, Xiaoli Zhu a, b, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | XBP1 is a key factor in the unfolded protein response in the endoplasmic reticulum. |
• | The IRE1α-XBP1 pathway is a highly promising clinical target. |
• | XBP1 operates as a key transcriptional factor and exhibits immune function. |
• | For the first time, we focused on the performance of XBP1 in a variety of tumours. |
• | We reviewed the effects of XBP1 expression on several processes, including autophagy, apoptosis, hypoxia, cell differentiation and invasion, metastasis, angiogenesis and drug resistance; we also reviewed potential antitumour therapies in research related to XBP1. |
Abstract |
X-box binding protein 1 (XBP1) is a unique basic-region leucine zipper (bZIP) transcription factor whose dynamic form is controlled by an alternative splicing response upon disturbance of homeostasis in the endoplasmic reticulum (ER) and activation of the unfolded protein response (UPR). XBP1 was first distinguished as a key regulator of major histocompatibility complex (MHC) class II gene expression in B cells. XBP1 communicates with the foremost conserved signalling component of the UPR and is essential for cell fate determination in response to ER stress (ERS). Here, we review recent advances in our understanding of this multifaceted translation component in cancer. In this review, we briefly discuss the role of XBP1 mediators in the UPR and the transcriptional function of XBP1. In addition, we describe how XBP1 operates as a key factor in tumour progression and metastasis. We mainly review XBP1′s expression, function and prognostic value in research on solid tumours. Finally, we discuss multiple approaches, especially those involving XBP1, that overcome the immunosuppressive effect of the UPR in cancer that could potentially be useful as antitumour therapies.
Le texte complet de cet article est disponible en PDF.Abbreviations : XBP1, IRE1α, UPR, ER, ERS, bZIP, PKR, PERK, ATF4, ATF6, GRP78, eIF2, RIDD, TCGA, HIF1, DCs, SCD, BL, SCD1, CTL, NF-κB, TGF-β, JNK, eIF2α, BCL2, GA, OSCC, STING, ASK1, TRAF2, VCP, HCC, B-ALL, T-ALL, MM, BTZ, VEGFA, EMT, LOXL2, TICs, TNBC, PDAC, NCOA3, PTPRN, PRNP, iNOS, CHOP, DK143, GCB, DLBCL, EZH2, ChIP, PCR, OBX, BMSCs, MMP, NSCLC, ROS, pADC, pSqCC, DFS, ALK, IV, TUDCA, Sor, PI3K, uPA, MG132, ESCC, GRP94, GADD34, PDIA6, MIBC, PCa
Keywords : X-box binding protein 1, Unfolded protein response, Inositol-requiring enzyme 1, Endoplasmic reticulum stress, Cancer
Plan
Vol 127
Article 110069- juillet 2020 Retour au numéro
Article précédent
- The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression
- Shuiping Liu, Qiujie Li, Ke Chen, Qin Zhang, Guohua Li, Lvjia Zhuo, Bingtao Zhai, Xinbing Sui, Xiaotong Hu, Tian Xie
- The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis
- Fenggen Yan, Fei Li, Junfeng Liu, Siqi Ye, Yu Zhang, Jinjing Jia, Hongyi Li, Dacan Chen, Xiumei Mo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?